Compare MiniMed Group Inc. Common Stock (MMED) vs Nextpower Inc. Common Stock (NXT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MiniMed Group Inc. Common Stock vs Nextpower Inc. Common Stock — how do they compare? MiniMed Group Inc. Common Stock trades at $16.74 (market cap $5.18B), while Nextpower Inc. Common Stock trades at $81.37 (market cap $13.47B). The key difference: Nextpower Inc. Common Stock is far larger — about 2.6× MiniMed Group Inc. Common Stock's market cap, and MiniMed Group Inc. Common Stock is trading nearer its 52-week high, Nextpower Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MiniMed Group Inc. Common Stock for 6 Days and Nextpower Inc. Common Stock for 0 Days on average.
| MMED | NXT | |
|---|---|---|
Market Cap | $5.18B | $13.47B |
Volume | 33,606,669 | 2,009,302 |
Sector | Health | Energy |
52-Week High | $23.84 | $156.40 |
52-Week Low | $10.80 | $77.93 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.98B | $12.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMED trades at $18.40, down 2.13% today, with technical indicators showing bearish momentum. The company reported revenue growth to $2.72B in 2025 but posted a net loss of -$250M. Recent news highlights Medtronic's exchange offer completion and MiniMed's new product launches. Analyst consensus remains strongly bullish with 100% buy ratings and a $25.73 price target, representing 40% upside potential from current levels.
Despite negative profitability metrics and bearish technical signals, MMED maintains strong analyst support and revenue growth trajectory. Key risks include persistent net losses, high short interest, and execution challenges in the competitive diabetes technology market. The stock offers potential upside if new product cycles drive margin improvement and profitability.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MiniMed Group Inc. Common Stock
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →
